Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
about
Skin patch and vaginal ring versus combined oral contraceptives for contraceptionCombination contraceptives: effects on weightCombination contraceptives: effects on weightSkin patch and vaginal ring versus combined oral contraceptives for contraceptionCombination contraceptives: effects on weightEvaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study.Intention to use a combined contraceptive method and decision after counselling in Switzerland--Swiss data from the European CHOICE study.Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).Hormonal contraception--what kind, when, and for whom?Review of the combined contraceptive vaginal ring, NuvaRing.A Randomised Controlled Trial Comparing the Efficacy and Side-Effects of Intravaginal Ring (Nuvaring(®)) With Combined Oral Hormonal Preparation in Dysfunctional Uterine Bleeding.The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspectiveEfficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles.Hormonal contraception in women with the metabolic syndrome: a narrative review.Reproductive and contraceptive issues in chronically ill adolescents.The vaginal ring (NuvaRing®) for contraception in adolescent women.The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction.Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health.Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages.Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use.Quality of sexual life of women using the contraceptive vaginal ring in extended cycles: preliminary report.Use of the NuvaRing hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus.Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.The long-term influence of combined oral contraceptives on body weight.Comparison of combined hormonal vaginal ring with ultralow-dose combined oral contraceptive pills in the management of heavy menstrual bleeding: A pilot study.
P2860
Q24197649-57390B22-0214-42EA-9B93-AC93C48243DEQ24200949-DE473E9C-82B1-40E7-8A70-FF7143720383Q24234337-4F862C5C-FAD5-4524-A39D-C4F5D20A5F07Q24236702-601D7DBF-CFC4-4648-B839-DA75BCF2450EQ24241209-46FEF00A-8380-4381-980B-A02255182AA8Q33589172-D21544CF-B5CC-44B9-8C21-4D545972F67DQ34112217-4A35A2F5-98D0-4E97-A330-4E50C8B45EFEQ34345741-AC58D5D5-23DA-427A-A7EC-48D0D662E478Q35144750-FECED017-5A3F-4A6A-8903-26D1E6A474F5Q36823561-45F2DBBC-F428-451C-A2DB-7B94B34E142BQ36831198-049B18DA-CC00-4CB0-82B7-CE0565788A17Q36904918-EBD99691-016C-444F-8802-ED3DF41754CFQ37233907-E6774298-1E02-4C3A-8009-E0AF61BB8AE6Q37548016-B8E65EAC-0C39-4026-A5A3-E3A06386FBBAQ37778835-5C0DDAAF-ED24-4B92-9A9A-3811ED08D6CAQ37810975-E06C5243-7164-497B-A96D-5911130140DEQ37880084-0A0FCEF3-D409-4A29-8AAF-783E5A0ADC83Q38056772-D02A1AE0-A580-456E-946B-78F7837870DCQ38132846-95CC2B53-2AE4-40DC-8CFF-F863C2FCA405Q42630326-2A90F850-E061-49EF-9479-0E7A09A4F7ECQ42844934-F40A36CA-069F-4876-AB0A-E6A8DB09B412Q43521079-8F478757-1130-4B11-91E8-38A25BCAF3FBQ46797821-59143A5D-61D2-41AF-884E-E8B1D63D9A28Q47137256-FC3A887C-79DD-4577-9B7F-214A2A5DBBD1Q47380258-5C9A645C-68DA-4DF1-8A34-3EC4F85540F6Q51837020-BB05C524-1090-41FA-80A7-EF79FFA768D2
P2860
Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@en
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@nl
type
label
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@en
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@nl
prefLabel
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@en
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@nl
P2093
P356
P1433
P1476
Effects on cycle control and b ...... tradiol and 3 mg drospirenone.
@en
P2093
Birkhäuser MH
Bjertnaes A
P304
P356
10.1093/HUMREP/DEL162
P407
P577
2006-06-08T00:00:00Z